★ Trastuzumab deruxtecan demonstrates a median progression-free survival of 13.2 months versus 8.1 with chemotherapy in HER2-low and HER2-ultralow hormone-positive metastatic breast cancer after one or more lines of endocrine therapy
Positive results from the phase 3 DESTINY-Breast06 trial showed that trastuzumab deruxtecan demonstrated a statistically…
0 Comments